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Abstract
Following an application from Granarolo S.p.A., submitted for authorisation of a health claim pursuant
to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the EFSA
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientiﬁc substantiation of a health claim related to a low-fat fermented milk and defence against
reactivation of Herpes simplex virus (HSV) in the orolabial epithelia. The scope of the application was
proposed to fall under a health claim based on newly developed scientiﬁc evidence. The food which
is the subject of the health claim, a low-fat fermented milk with a combination of fructo-
oligosaccharides and live Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus
(Z57) and Lactobacillus delbrueckii subsp. Bulgaricus (LB2), is sufﬁciently characterised. Defence
against reactivation of HSV in the orolabial epithelia is a beneﬁcial physiological effect. The
Panel considers that no conclusions can be drawn from three out of the four human intervention
studies, which were provided by the applicant, for the scientiﬁc substantiation of the claim. In
weighing the evidence, the Panel took into account that one human intervention study from which
scientiﬁc conclusions can be drawn does not show a consistent effect of daily consumption of the low-
fat fermented milk on the reduction in incidence of herpes labialis (HL) lesions after ultraviolet B (UVB)
exposure and that no convincing evidence was provided for a mechanism by which the low-fat
fermented milk could contribute to the defence against reactivation of HSV in the orolabial epithelia.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of the low-fat fermented milk, which is the subject of the health claim, and defence
against reactivation of HSV in the orolabial epithelia.
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Summary
Following an application from Granarolo S.p.A., submitted for authorisation of a health claim
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the
scientiﬁc substantiation of a health claim related to a low-fat fermented milk and defence against
reactivation of Herpes simplex virus (HSV) in the orolabial epithelia.
The scope of the application was proposed to fall under a health claim based on newly developed
scientiﬁc evidence. The application included a request for the protection of proprietary data.
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the European Food Safety Authority (EFSA) general guidance for stakeholders on health claim
applications and the guidance on the scientiﬁc requirements for health claims related to the immune
system, the gastrointestinal tract and defence against pathogenic microorganisms.
The food that is the subject of the health claim is a low-fat fermented milk with a combination
of fructo-oligosaccharides (FOS) and live Lactobacillus rhamnosus GG (LGG; ATCC 53103),
Streptococcus thermophilus (Z57) and Lactobacillus delbrueckii subsp. Bulgaricus (LB2). The Panel considers
that the low-fat fermented milk, the food which is the subject of the health claim, is sufﬁciently characterised.
The claimed effect proposed by the applicant is ‘helps to reduce recurrence of lip cold sores caused
by Herpes simplex virus infection’ and the target population proposed by the applicant is the ‘general
healthy population’. Taking into account the EFSA guidance for claims on the immune system, the
Panel considers that the claimed effect relates to the defence against reactivation of HSV in the
orolabial epithelia, which virus may cause the occurrence of lip cold sores. The incidence of
herpes labialis (HL) lesions at the end of the study is the appropriate outcome variable to assess this
claimed effect. The Panel considers that defence against reactivation of HSV in the orolabial epithelia is
a beneﬁcial physiological effect.
The applicant provided four human intervention studies as being pertinent to the health claim.
Two of these studies reported faecal counts of LGG and biﬁdobacteria following the consumption of
a yoghurt added with/without LGG and FOS or fermented milks containing several bacterial strains.
The Panel considers that no conclusions can be drawn from these studies on an effect of the low-fat
fermented milk, which is the subject of the health claim, on incidence of HL lesions.
Two unpublished reports were provided by the applicant on human intervention studies on the
effect of the low-fat fermented milk, which is the subject of the health claim, on incidence of HL
lesions. In these studies, participants were randomised to consume the low-fat fermented milk or
placebo for 35 or 126 days, respectively. After 19 days of consumption of the study products,
participants were exposed to ultraviolet radiation (UVR). At different time points after UV exposure,
participants had clinical examinations to ascertain recurrence and progression of HL lesions.
With respect to the ﬁrst unpublished study, owing to the inconsistent information submitted by the
applicant in reply to requests for clariﬁcations during the evaluation procedure, the information on this
study was considered insufﬁcient to allow a full scientiﬁc evaluation. The Panel considers that no
conclusions can be drawn from this study for the scientiﬁc substantiation of the claim.
With respect to the second unpublished study, the Panel notes the inconsistency of the results
between the intention-to-treat (ITT) and per protocol (PP) analyses, and that no explanations for the
different results in the two analyses have been provided. The Panel considers that this study does not
show a consistent effect of daily consumption of the low-fat fermented milk, which is the subject of
the health claim, on the reduction in incidence of HL lesions after UVB exposure.
The applicant indicated that the low-fat fermented milk could exert the claimed effect by
stimulation of the immune system which may affect the HSV latency reactivation. In this respect, the
two unpublished studies, which were described above, investigated the effect of the low-fat fermented
milk on immunological parameters. The Panel considers that these studies did not show a consistent
effect of daily consumption of the low-fat fermented milk on immunological parameters. The applicant
also provided in vitro and animal studies in support of a mechanism by which the low-fat fermented
milk could exert the claimed effect.
The Panel considers that the human, animal and in vitro studies submitted by the applicant
provided no convincing evidence for a mechanism by which the low-fat fermented milk, which is the
subject of the health claim, could exert the claimed effect.
In weighing the evidence, the Panel took into account that one human intervention study from
which scientiﬁc conclusions can be drawn does not show a consistent effect of daily consumption of
the low-fat fermented milk on the reduction in incidence of HL lesions after UVB exposure, and that no
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convincing evidence was provided for a mechanism by which the low-fat fermented milk could
contribute to the defence against reactivation of HSV in the orolabial epithelia.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of the low-fat fermented milk, which is the subject of the health claim, and defence
against reactivation of HSV in the orolabial epithelia.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health) which are based on newly developed
scientiﬁc evidence, or which include a request for the protection of proprietary data, to the Community
list of permitted claims referred to in Article 13(3).
According to Article 18 of this Regulation, an application for inclusion in the Community list of
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national
competent authority of a Member State, which will make the application and any supplementary
information supplied by the applicant available to the European Food Safety Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientiﬁc substantiation of a health claim related to: low-fat fermented milk and defence
against reactivation of Herpes simplex virus (HSV) in the orolabial epithelia.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of low-fat fermented milk, a positive assessment of its safety nor a decision on whether low-
fat fermented milk is, or is not, classiﬁed as a foodstuff. It should be noted that such an assessment is
not foreseen in the framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
2.1.1.1. Food as stated by the applicant
According to the applicant, the food for which the health claim is made is a low-fat fermented milk
with a combination of fructo-oligosaccharides (FOS) and live Lactobacillus rhamnosus GG (LGG;
ATCC 53103), Streptococcus thermophilus (Z57) and Lactobacillus delbrueckii subsp. bulgaricus (LB2).
2.1.1.2. Health relationship as claimed by the applicant
According to the applicant, the claimed effect is ‘helps to reduce recurrence of lip cold sores caused
by Herpes simplex virus infection in healthy susceptible individuals’.
Herpes simplex virus type 1 infects mainly the oropharyngeal mucosa causing Herpes simplex labialis
or Herpes labialis (HL) which manifests in the form of skin lesions commonly known as cold sores.
The outcome variable proposed by the applicant for the assessment of the health claim is the
evaluation of the number of subjects who presented lesions in the region of the lips (lip cold sores) at
different time points after ultraviolet (UV) exposure.
2.1.1.3. Mechanism by which the food could exert the claimed effect as proposed by the
applicant
The applicant indicated that the mechanism by which the low-fat fermented milk could exert the
claimed effect involves the stimulation of the immune system. The applicant also referred to in vitro
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
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studies which indicated that Lactobacillus rhamnosus GG (ATCC 53103) could promote survival of
epithelial cells and induce transcription of inﬂammatory and innate immune response genes.
2.1.1.4. Wording of the health claim as proposed by the applicant
The applicant has proposed the following wording for the health claim: ‘Consumption of low-fat
fermented milk with a combination of fructo-oligosaccharides (FOS) and live Lactobacillus rhamnosus GG
(ATCC 53103), Streptococcus thermophilus (Z57) and Lactobacillus delbrueckii subsp. bulgaricus (LB2)
helps to reduce recurrence of lip cold sores caused by Herpes simplex virus infection in healthy
susceptible individuals’.
2.1.1.5. Speciﬁc conditions of use as proposed by the applicant
The target population proposed by the applicant is the general healthy population.
The applicant has proposed a daily consumption of 90 g of the low-fat fermented milk at breakfast.
The low-fat fermented milk, which contains 89% of milk, could reasonably be consumed as part of a
balanced diet as a portion of dairy product.
2.1.2. Data provided by the applicant
Health claim application on ‘consumption of Lactobacillus rhamnosus GG (ATCC 53103) and fructo-
oligosaccharides (FOS) helps to reduce recurrence of lip cold sores caused by Herpes simplex virus
infection in healthy susceptible individuals’ pursuant to Article 13.5 of Regulation 1924/2006, presented
in a common and structured format as outlined in the Scientiﬁc and technical guidance for the
preparation and presentation of applications for authorisation of health claims (EFSA NDA Panel, 2011).
As outlined in the General guidance for stakeholders on health claim applications, it is the
responsibility of the applicant to provide the totality of the available evidence (EFSA NDA Panel, 2016a).
This health claim application includes a request for the protection of proprietary data in accordance
with Article 21 of Regulation (EC) No 1924/2006 for two unpublished study reports (Broccoletti et al.,
2009; La Placa et al., 2014) and for data on the composition, manufacturing process and stability of
the low-fat fermented milk.
2.2. Methodologies
The general approach of the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) for the
evaluation of health claim applications is outlined in the EFSA general guidance for stakeholders on
health claim applications (EFSA NDA Panel, 2016a).
The scientiﬁc requirements for health claims related to the immune system, the gastrointestinal
tract and defence against pathogenic microorganisms are outlined in the speciﬁc EFSA guidance (EFSA
NDA Panel, 2016b).
3. Assessment
3.1. Characterisation of the food
The food that is the subject of the health claim is a low-fat fermented milk with a combination of
FOS and live Lactobacillus rhamnosus GG (ATCC 53103), Streptococcus thermophilus (Z57) and
Lactobacillus delbrueckii subsp. bulgaricus (LB2).
The strain LGG has been identiﬁed and characterised at species and strain level using both
phenotypic and genotypic methods. The Panel notes that the culture collection number from the
American Type Culture Collection (ATCC 53103) is given. The genome sequence of LGG has been
published by Kankainen et al. (2009).
FOS are produced by partial enzymatic hydrolysis of chicory inulin. FOS consist of a mixture of
oligosaccharides which are composed of fructose units linked together by b(2–1) linkages and mainly
terminate with glucose unit. The total number of fructose or glucose units (degree of polymerisation)
of oligofructose ranges mainly between 2 and 8.
Information on the genome sequence of S. thermophilus (Z57) and L. delbrueckii subsp. bulgaricus
(LB2) was provided by the applicant.
The composition of a daily serving (90 g) of the fermented milk has been provided: 1.71 g of fat,
9.63 g of carbohydrates, 2.43 g of proteins, 1.8 9 109 colony forming unit (cfu) of LGG, 2.79 g of
FOS, 72 9 109 cfu of S. thermophilus and 0.9 9 109 cfu of L. delbrueckii subsp. bulgaricus.
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Information pertaining to the manufacturing process and stability tests has been provided by the
applicant.
The Panel considers that the low-fat fermented milk with a combination of FOS and live LGG,
S. thermophilus (Z57) and L. bulgaricus (LB2), the food which is the subject of the health claim, is
sufﬁciently characterised.
3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is ‘helps to reduce recurrence of lip cold sores caused
by Herpes simplex virus infection’. The target population proposed by the applicant is the ‘general
healthy population’.
The clinical outcome proposed by the applicant to evaluate the claimed effect is the between-group
difference in the number of participants who presented herpes labialis (HL) lesions at different time
points after UV exposure from human intervention studies.
Taking into account the EFSA guidance for claims on the immune system (EFSA NDA Panel, 2016b),
the Panel considers that the claimed effect relates to the defence against reactivation of HSV in the
orolabial epithelia, which virus may cause the occurrence of lip cold sores. As indicated in this
guidance, health claims related to defence against pathogens (such as defence against reactivation of
HSV) can be substantiated by human intervention studies which investigate outcomes related to
infections (e.g. incidence, severity and/or duration of symptoms). In the context of this health claim
application, the Panel considers that between-group differences in the incidence of HL lesions at the
end of the study (i.e. total number of participants who experienced at least one HL lesion from UV
radiation (UVR) exposure out of those free of lesions at the time of UVR exposure) is the appropriate
outcome variable to assess this claimed effect.
The Panel considers that defence against reactivation of HSV in the orolabial epithelia is a beneﬁcial
physiological effect.
3.3. Scientiﬁc substantiation of the claimed effect
The applicant performed a literature search in PubMed and US National Institutes of Health clinical
trial database using an extensive list of keywords.
The applicant provided four human intervention studies as being pertinent to the health claim
(Zanini et al., 2007; Broccoletti et al., 2009; Granata et al., 2013; La Placa et al., 2014).
The double-blind, randomised, placebo-controlled study by Granata et al. (2013) reported faecal
counts of LGG and biﬁdobacteria following consumption of a yoghurt added with or without LGG and
FOS. The cross-over, single-blind, no-randomised study by Zanini et al. (2007) reported faecal counts
of lactobacilli and biﬁdobacteria following consumption of fermented milks containing several bacterial
strains. The Panel considers that no conclusions can be drawn from these studies on an effect of the
low-fat fermented milk, which is the subject of the health claim, on incidence of HL lesions.
3.3.1. Human intervention studies on the effect of the low-fat fermented milk on
incidence of HL lesions
The applicant provided two unpublished reports on human intervention studies on the effect of the
low-fat fermented milk, which is the subject of the health claim, on incidence of HL lesions.
In the placebo-controlled, single-centre study by Broccoletti et al. (2009), 78 adults were
randomised to consume daily 90 g of fermented milks for 35 days: the fermented low-fat milk which is
the subject of the health claim (LGG plus FOS group; n = 18, which included 10 females); a low-fat
milk fermented with LGG, L. delbrueckii subsp. bulgaricus, and S. thermophilus, but without FOS (LGG
group; n = 21, which included 12 females); a low-fat milk fermented with L. delbrueckii subsp.
bulgaricus, S. thermophilus and added with FOS (FOS group; n = 19, which included nine females); or
placebo (n = 20, which included 10 females). The placebo consisted of a low-fat milk, without LGG
and FOS, which was fermented with L. delbrueckii subsp. bulgaricus and S. thermophilus, and then
pasteurised. Randomisation was stratiﬁed by age and gender.
The amount of FOS and LGG per bottle was 2.79 g and 2 x 109 cfu, respectively, whereas the
amount of S. thermophilus and L. delbrueckii subsp. bulgaricus was 72 x 109 cfu and 0.9 x 109 cfu,
respectively. The identity of the study products were blinded to participants, support staff members
and investigators. The clinical study protocol was approved by the Ethical Committee of Molinette
Hospital in Turin (Italy).
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Individuals without HL lesions at the time of recruitment, with no more than three HL episodes
after exposure to sunlight in the previous year and with Fitzpatrick skin type from I to IV were enrolled
in this study. Individuals were excluded if they had HL episodes or if they consumed ‘probiotic
products’ in the month prior to the study; or if they were under medication which could interfere with
the immune response (e.g. acyclovir). Concomitant medications and compliance were recorded in
diaries by participants. The Panel noted that some participants had HL lesions at screening (n = 1 per
group) and at baseline (i.e. randomisation) (n = 2 in the placebo and LGG plus FOS groups; n = 1 in
the LGG group). Upon EFSA’s request for clariﬁcation on this point, the applicant indicated that
individuals with HL lesions at screening were allowed to participate in the study as their HL episodes
were considered by the investigator to be at a late and ending stage. The applicant also indicated the
‘HL lesions at baseline’ was not an exclusion criterion in this study.
All participants consumed placebo mini-drinks for 14 days and then they were randomised to
consume the study products (fermented milks with LGG plus FOS, only LGG, only FOS or placebo) for
35 days. After 19 days of consumption of the study products, participants were exposed to UVR,
which was determined through minimal erythema dose (MED). No rationale was provided for giving
UVR amounts that related to the MED, rather than a standard dose of UVR.
After 2, 9 and 16 days from UVR exposure, participants had clinical examinations to ascertain
recurrence and progression of HL lesions. At each visit, the following parameters were assessed: lesion
development (by classiﬁcation of lesion stage and photos), duration (i.e. time to healing deﬁned as
either loss of the hard crust or return to normal skin) and lesion size (as a product of the length and
the width of the lesion). HL signs and symptoms (i.e. dimension, crust, swelling, tenderness) and pain
were self-assessed on a 0–4 score scale and visual analogue scale (VAS), respectively. At baseline and
at the end of the study, immunological parameters were measured and quality of life was assessed
through a SF-36 questionnaire.
Between-group difference in the number of participants with HL lesions at different time points (i.e.
at 2, 9 and 16 days after UVR exposure) was the primary outcome of this study.
It is reported in the study that a sample size of 80 participants (i.e. 20 per group) was needed to
yield a minimum of 83% statistical power and two-sided 5% signiﬁcance level.
Fisher’s exact test was used to analyse differences in the incidence of HL lesions, new lesions and
lesion characteristics among groups. The analysis of variance (ANOVA) was used to analyse differences
in pain and quality of life questionnaire among groups; whereas the Wilcoxon rank sum test was used
to compare the differences in immune parameters among groups. All tests were two-sided and the
signiﬁcance was set at 5% level. For unpaired comparisons, the signiﬁcance was set at the 0.008 level
(Bonferroni’s method).
Statistical analyses of the outcomes investigated were presented for the intention-to-treat (ITT)
population and the per protocol (PP) population (i.e. participants who did not violate the protocol and
who did not present HL lesions at the time of UVR exposure). The last observation carried forward
method was used for imputing missing values in the ITT analysis.
The ITT and PP populations consisted of 78 and 71 participants, respectively. Seven participants
were not included in the PP population owing to HL lesions present on the day of the UVR exposure
(n = 1 in the placebo group and n = 2 in each of the remaining groups).
At baseline, there were no statistically signiﬁcant differences between groups in terms of gender,
age, body mass index (BMI), human leukocyte antigen, UVR exposure time and compliance, which
ranged between 99.5% and 100%.
The between-group differences in the number of participants with HL lesions were presented at
different time points (i.e. at 2, 9 and 16 days after UVR exposure) for the ITT and PP population.
However, the Panel considers that between-group differences in the incidence of HL lesions at the end
of the study (i.e. total number of participants who experienced at least one HL lesion from UVR
exposure out of those free of lesions at the time of UVR exposure) is the appropriate outcome variable
to assess the claimed effect. Therefore, the applicant was requested to provide the incidence of HL
lesions for the ITT and PP population. The Panel notes that the additional information submitted by the
applicant in reply to these requests is inconsistent and insufﬁcient to allow a full scientiﬁc evaluation of
this study (e.g. the number of participants in the study groups in the ITT and PP populations did not
match the number of participants declared in the study report; the incidence calculated for some study
groups did not match the number of individuals with at least one HL lesion reported in those groups;
in a second analysis provided, the incidence in the control group was calculated as the number of
lesions, rather than as the number of participants with at least one lesion, out of the number of
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subjects at the time of the UVR exposure). The Panel considers that no conclusions can be drawn from
this study for the scientiﬁc substantiation of the claim.
In the placebo-controlled, double-blind, multicentre study by La Placa et al. (2014), 157 adults
were randomised to consume daily 90 g of the low-fat fermented milk which is the subject of the
health claim (n = 78, which included 65 females) or placebo (n = 79, which included 59 females) for
126 days. The placebo consisted of low-fat milk, without LGG and FOS, which was fermented with
L. delbrueckii subsp. bulgaricus and S. thermophilus, and then pasteurised.
The amount of FOS and LGG per bottle was 2.79 g and 2 x 109 cfu, respectively, whereas the
amount of S. thermophilus and L. delbrueckii subsp. bulgaricus was 72 x 109 cfu and 0.9 x 109 cfu,
respectively. The clinical study protocol was approved by the Ethical Committee of Azienda
Ospedaliero-Universitaria of Bologna (Italy).
Individuals without HL lesions at the time of recruitment and at baseline, with a history of recurrent
HL (two to four episodes) after exposure to sunlight in the previous year and with Fitzpatrick skin type
I–IV were enrolled in this study. Individuals were excluded if they were under medication which could
interfere with the immune response (e.g. acyclovir). Concomitant medications and compliance were
recorded in diaries by participants.
All participants consumed placebo mini-drinks for 14 days and then they were randomised to
consume the study products for 126 days. After 19 days of consumption of the study products,
participants were exposed to UVB radiation, which was determined through MED. No rationale was
provided for giving UVB amounts that related to the MED, rather than a standard dose of UVB.
After 2, 9, 16 and 107 days (end of the study) from UVB exposure, participants underwent clinical
examinations to ascertain the recurrence and progression of HL lesions. At each visit, the following
parameters were assessed: lesion development (by classiﬁcation of lesion stage and photos), duration
(i.e. time to healing deﬁned as either loss of the hard crust or return to normal skin) and lesion size
(longest measure taken). HL signs and symptoms (i.e. crust, swelling, tenderness, overall severity) and
pain were self-assessed on a 0–4 scores scale and VAS scale, respectively. At randomisation, after
16 and 107 days from UVB exposure antibody concentrations were measured and quality of life was
assessed through a SF-36 questionnaire.
Between-group differences in the number of participants with/without HL lesions after 16 days from
UVB exposure was the primary outcome of this study.
A sample size of 152 participants was determined to detect a 30% difference in the incidence of HL
lesions between group (power 90%; two-sided 5% signiﬁcance level).
Fisher’s exact test was used to analyse differences in the incidence of HL lesions between groups.
Student’s t test was used to compare duration, and lesion dimensions between groups. Wilcoxon Rank
Sum test was used to analyse immunological parameters.
All participants who consumed at least one dose of intervention or placebo were included in the ITT
population (n = 78 in the intervention and n = 79 in the placebo groups, respectively). The PP
population consisted of 59 participants in the intervention group and 57 participants in the placebo
group. The PP population excluded participants who developed HL before the UVB exposure (n = 6 in
both groups), who had protocol violations (n = 7 in the intervention and n = 6 in the placebo groups,
respectively) or discontinued the study (n = 6 in the intervention and n = 10 in the placebo groups,
respectively).
Statistical analyses of the outcomes investigated were presented for the ITT and PP population.
Upon EFSA’s request for clariﬁcations, the applicant indicated that all available data were considered
for the ITT statistical analysis and no method was used to impute missing data.
At baseline, no statistically signiﬁcant differences between groups were reported in terms of gender,
age, BMI, Fitzpatrick skin type. Compliance to the study products was not statistically signiﬁcant
different between groups (81.4% in the intervention and 75.5% in the placebo groups, respectively).
The between-group differences in the number of subjects with HL lesions, which also included the
relapses of HL on the same subject, were presented for the ITT population, with a conﬁrmatory
analysis performed in the PP population. In the ITT population, there was no statistically signiﬁcant
between-group difference in the number of subjects with HL lesions after 16 days from UVB exposure.
In the PP population, the number of subjects with HL lesions was lower in the intervention group as
compared with the placebo group after 16 days from UVB exposure (number of participants with HL
lesions: n = 8 in the intervention and n = 17 in the placebo groups, respectively; p = 0.042).
In the ITT population, there was no statistically signiﬁcant between-group difference in the total
number of participants with HL lesions at the end of the study (i.e. after 107 days from UVB
exposure), whereas the study reported a statistically signiﬁcant reduction in the total number of
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participants with HL lesions in the intervention group as compared with the placebo group in the PP
population (n = 13 in the intervention and n = 25 in the placebo groups, respectively; p = 0.02).
In the PP population, there were no statistically signiﬁcant between-group differences in the other
parameters investigated at the end of the study (i.e. time to healing, lesion size, self-assessed scores
on signs and symptoms of HL lesions and self-assessed scores in the quality of life questionnaire). The
authors indicated that a statistically signiﬁcant difference was observed in the self-assessed average
scores of pain between groups.
The Panel notes the inconsistency of the results between the ITT and PP analyses. The Panel also
notes that no explanations for the different results in the two analyses have been provided. The
Panel considers that this study does not show a consistent effect of daily consumption of the low-fat
fermented milk, which is the subject of the health claim, on the reduction in incidence of HL lesions
after UVB exposure.
3.3.2. Studies on the mechanism by which the low-fat fermented milk could
exert the claimed effect
The applicant indicated that the low-fat fermented milk, which is the subject of the health claim,
could exert the claimed effect by stimulation of the immune system which may affect the HSV latency
reactivation. In this respect, the two unpublished studies which were described in the previous section
(Broccoletti et al., 2009; La Placa et al., 2014) investigated the effect of the low-fat fermented milk on
immunological parameters.
The study by Broccoletti et al. (2009) reported a statistically signiﬁcant increase in HSV-speciﬁc
immunoglobulin 3 (IG3) levels in the low-fat fermented milk group as compared to the placebo group
(p = 0.0001); whereas there was no statistically signiﬁcant difference in HSV-speciﬁc IG1 or IG4 levels
between groups. This study also reported a statistically signiﬁcant decrease in interferon-c (IFN-c)
levels in the low-fat fermented milk group as compared to the placebo group (p = 0.003). A
statistically signiﬁcant increase in ‘% PMN that phagocytose candida’ and in ‘% PMN that kill candida’
was observed in the low-fat fermented milk group as compared to the placebo group (p = 0.008 and
0.0001, respectively).
This study did not report any other statistically signiﬁcant differences between the low-fat fermented
milk and the placebo groups in the other parameters investigated (i.e. cytokines interleukin-2 and
interleukin-10; immune phenotypes (CD4, CD8, CD4/CD25, CD8/CD25, CD4/CD45RO, CD8/CD45RO,
CD8/CD38/CD45RO); NK activity – % of dead target cells; pentamers – % of positive cells; IFN-c
ELISPOT phenotype).
The study by La Placa et al. (2014) reported a statistically signiﬁcant between-group difference in
CXCL10 levels at day 16 after UVB exposure in a subgroup of participants with HL lesions (p = 0.006);
whereas no other statistically signiﬁcant between-group differences were reported in any of the other
immunological parameters investigated (i.e. levels of IgG1, IgG3, IgG4, NK activity, CXCL10 at day 16
after UVB exposure and at the end of the study).
The Panel considers that the studies by Broccoletti et al. (2009) and La Placa et al. (2014) did not
show a consistent effect of daily consumption of the low-fat fermented milk, which is the subject of
the health claim, on immunological parameters.
The applicant also provided in vitro and animal studies in support of a mechanism by which the
low-fat fermented milk could exert the claimed effect. The Panel notes that some of these studies
were carried out with bacterial strains other than those in the low-fat fermented milk that is the
subject of the health claim.
The in vitro studies by Yan and Polk (2002) and Tao et al. (2006) indicated that LGG promoted the
survival of intestinal epithelial cells by the inhibition of proapoptotic p38/mitogen-activated protein
kinase. The applicant hypothesised that LGG could counteract the activation of the p38 signalling
apoptotic pathways, which were suggested to be stimulated by HSV-1 proteins (Gillis et al., 2009).
The in vitro study by Miettinen et al. (2012) indicated that LGG induced an alteration of gene
expression proﬁles and an increase in the production of interleukin-1b (IL-1b) in human primary
macrophages. Considering that HSV-1 appears to prevent secretion of IL-1b in the intracellular space
(Milora et al., 2014), the applicant hypothesised that LGG helps to re-establish the concentration of IL-1b.
Liu et al. (2013) investigated the effect of LGG on diarrhoea episodes, histopathology of the ileum
and serum cytokine responses in a pig model of virulent human rotavirus (HRV) infection.
Capitan-Ca~nadas et al. (2014) reported the effect of non-digestible oligosaccharides, including FOS,
on cytokine secretion in primary rat monocytes and in human peripheral blood monocytes.
Low-fat fermented milk and defence against reactivation of Herpes simplex virus
www.efsa.europa.eu/efsajournal 11 EFSA Journal 2016;14(7):4538
The Panel considers that the human, animal and in vitro studies submitted by the applicant
provided no convincing evidence for a mechanism by which the low-fat fermented milk, which is the
subject of the health claim, could exert the claimed effect.
3.3.3. Weighing of the evidence
In weighing the evidence, the Panel took into account that one human intervention study from
which scientiﬁc conclusions can be drawn does not show a consistent effect of daily consumption of
the low-fat fermented milk on the reduction in incidence of HL lesions after UVB exposure and that no
convincing evidence was provided for a mechanism by which the low-fat fermented milk could
contribute to the defence against reactivation of HSV in the orolabial epithelia.
The Panel concludes that a cause and effect relationship has not been established between the
consumption of the low-fat fermented milk, which is the subject of the health claim, and defence
against reactivation of HSV in the orolabial epithelia.
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• the low-fat fermented milk with a combination of FOS and live LGG, S. thermophilus (Z57) and
L. bulgaricus (LB2), the food which is the subject of the health claim, is sufﬁciently
characterised.
• the claimed effect proposed by the applicant is ‘helps to reduce recurrence of lip cold sores
caused by Herpes simplex virus infection’. The target population proposed by the applicant is
the ‘general healthy population’. Defence against reactivation of HSV in the orolabial epithelia is
a beneﬁcial physiological effect
• a cause and effect relationship has not been established between the consumption of the low-
fat fermented milk and defence against reactivation of HSV in the orolabial epithelia.
Steps taken by EFSA
1) Health claim application on ‘consumption of Lactobacillus rhamnosus GG (ATCC 53103) and
fructo-oligosaccharides (FOS) helps to reduce recurrence of lip cold sores caused by
Herpes simplex virus infection in healthy susceptible individuals’ pursuant to Article 13(5) of
Regulation (EC) No 1924/2006 (Claim serial No: 0439_IT). Submitted by Granarolo S.p.A.,
Via Cadriano 27/2, 40127, Bologna, Italy.
2) This application was received by EFSA on 31/8/2015.
3) The scope of the application was proposed to fall under a health claim based on newly
developed scientiﬁc evidence. The application included a request for the protection of
proprietary data.
4) On 9/10/2015, during the validation process of the application, EFSA sent a request to the
applicant to provide missing information.
5) On 14/12/2015, EFSA received the missing information as submitted by the applicant.
6) The scientiﬁc evaluation procedure started on 16/12/2015.
7) On 20/1/2016, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 09/02/2016 and was restarted on 24/2/2016, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
8) On 25/2/2016, EFSA received the applicant’s reply (which was made available to EFSA in
electronic format on 24/2/2016).
9) On 16/3/2016, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientiﬁc evaluation was suspended on 11/4/2016 and was restarted on 26/4/2016, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
10) On 28/4/2016, EFSA received the applicant’s reply.
11) During its meeting on 28/6/2016, the NDA Panel, having evaluated the data, adopted an
opinion on the scientiﬁc substantiation of a health claim related to low-fat fermented milk
and defence against reactivation of Herpes simplex virus in the orolabial epithelia.
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Abbreviations
ANOVA analysis of variance
ATCC American Type Culture Collection
BMI body mass index
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LGG Lactobacillus rhamnosus GG (ATCC 53103)
MED minimal erythema dose




VAS visual analogue scale
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